1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | REL-1017 / esmethadone (investigational; not yet FDA-approved as of mid-2024) |
| structure | File | |
| classes | List of String, delimiter: , | NMDA receptor antagonist (uncompetitive • low-trapping) |
| mechanism | String | |
| uses | String | Investigational for major depressive disorder; trials underway (phase 3 mixed results) |
| starting_dose | String | Trials use 25 mg or 50 mg PO daily |
| preparations | String | Investigational oral capsule |
| fda_max | String | Not yet approved |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Rapid (within 1 week in trials) |
| duration | String | Daily dosing |
| halflife | String | Not formally established |
| bioavailability | String | Oral bioavailability suitable for daily dosing |
| pregnancy | String | Investigational |
| legal | String | Investigational |
